BioSpace

Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues

Novartis will continue to study Fabhalta in other indications, with late-stage studies in two rare diseases—atypical haemolytic uraemic syndrome and generalized myasthenia gravis—expected to read out later this year and next year, respectively.

By BioSpace

1 min read
Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights